The Russian Ministry of Health has registered the drug Forsedeno (INN denosumab), the first domestic biosimilar of an original targeted drug for the treatment of osteoporosis. Petrovax Pharm is the manufacturer and holder of the registration certificate.
The efficacy and safety of the drug The rights to the denosumab biosimilar were acquired by Petrovax Pharm from the Iranian company AryoGen Pharma (part of the CinnaGen Group) under a license agreement providing for full localization of production in Russia. were confirmed in a multicenter phase 3 clinical trial. The cost of the drug will be lower compared to the original product, which will potentially expand access to therapy for patients, and more than 50,000 patients have already received therapy, the company reported.
Earlier, PSK Pharma has registered Respiforb Air, a combination of budesonide and formoterol, for the treatment of bronchial asthma.
